Referencia número: HY-B1730

Phensuximide

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.41%
No. CAS: 86-34-0
Fòrmula: C₁₁H₁₁NO₂
Peso molecular:189.21

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Phensuximide Chemical Structure

No. CAS: 86-34-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

IC50: cyclic AMP and cyclic GMP accumulation^[2]

In Vitro

Phensuximide produce depolarization-induced accumulation of cyclic GMP or cyclic AMP levels with ID₅₀ values of 8.00 mM or 6.20 mM in incubated slices of mouse cerebral cortex^[2].
Phensuximide (0.5-2.0 mM) has the ability to competitively inhibit mephenytoin 4-hydroxylase activity in human liver microsomes, the K_i and K_m values are 559 μM and 235 μM, respectively^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Phensuximide (intraperitoneal injection; 1.25 mmol/kg; single dose) induces mild changes in renal function, including: trace hematuria, increased proteinuria and decreased paminohippurate uptake in Sprague-Dawley rats^[1].
Phensuximide (intraperitoneal injection; 0.3 or 0.6 mmol/kg; 5-7 days) results in transient hematuria and proteinuria, but no change in the other renal function parameters studied. It is concluded that phensuximide produces mild, transient renal effects in Fischer 344 rats, and that the Fischer 344 rat is a suitable model for studying phensuximide-induced toxicity to the urinary tract^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Fischer 344 rats^[1]
Dosage:

0.3 or 0.6 mmol/kg
Administration:

Intraperitoneal injection; 5-7 days
Result:

Induced urotoxicity following daily administration for 5-7 days in Fischer 344 rats.

Chemical Information

No. CAS 86-34-0
Appearance Solid
Peso molecular 189.21
Fòrmula C₁₁H₁₁NO₂
Color White to off-white
SMILES

O=C(C(C1=CC=CC=C1)C2)N(C)C2=O
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Cell Death Dis

FDA-approved phensuximide inhibits RIPK1-dependent immunogenic cell death. [Abstract]

2025 Jun 2;16(1):426. PMID: 40456737

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (528.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.2851 mL

26.4257 mL

52.8513 mL

5 mM

1.0570 mL

5.2851 mL

10.5703 mL

10 mM

0.5285 mL

2.6426 mL

5.2851 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (277 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. G O Rankin, et al. Urinary Tract Effects of Phensuximide in the Sprague-Dawley and Fischer 344 Rat. J Appl Toxicol. . 1986 Oct;6(5):349-56. [Content Brief]

[2]. J A Ferrendelli, et al. Inhibitory Effects of Anticonvulsant Drugs on Cyclic Nucleotide Accumulation in Brain. Ann Neurol. 1979 Jun;5(6):533-8. [Content Brief]

[3]. J G MILLICHAP, et al. Milontin: A New Drug in the Treatment of Petit Mal.Lancet. 1952 Nov 8;2(6741):907-10. [Content Brief]

[4]. S D Hall,et al. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. The JOURNAL OP PHARMAcOLOGY AND EXPERIMENTAL THERAPEUTICS

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.2851 mL	26.4257 mL	52.8513 mL	132.1283 mL
	5 mM	1.0570 mL	5.2851 mL	10.5703 mL	26.4257 mL
	10 mM	0.5285 mL	2.6426 mL	5.2851 mL	13.2128 mL
	15 mM	0.3523 mL	1.7617 mL	3.5234 mL	8.8086 mL
	20 mM	0.2643 mL	1.3213 mL	2.6426 mL	6.6064 mL
	25 mM	0.2114 mL	1.0570 mL	2.1141 mL	5.2851 mL
	30 mM	0.1762 mL	0.8809 mL	1.7617 mL	4.4043 mL
	40 mM	0.1321 mL	0.6606 mL	1.3213 mL	3.3032 mL
	50 mM	0.1057 mL	0.5285 mL	1.0570 mL	2.6426 mL
	60 mM	0.0881 mL	0.4404 mL	0.8809 mL	2.2021 mL
	80 mM	0.0661 mL	0.3303 mL	0.6606 mL	1.6516 mL
	100 mM	0.0529 mL	0.2643 mL	0.5285 mL	1.3213 mL

Keywords

Phensuximide

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Phensuximide

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Pattern Recognition Receptors Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Phensuximide

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Phensuximide

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Pattern Recognition Receptors Library

3D Diverse Fragment Library

Publications Citing Use of MedChemExpress (MCE) Phensuximide

Actividad biológica

Chemical Information

Publications (2)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Phensuximide Related Classifications

HY-B1730 Related Classifications